No Data
Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31
Kymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 Symposium
Kymera's IND Application for STAT6 Degrader Gets FDA Clearance
Kymera Gets FDA Clearance for Phase 1 Testing of KT-621
The FDA Clears Kymera Therapeutics' Investigational New Drug Application For KT-621, The Company Expects To Initiate Dosing In A Phase 1 Trial In Healthy Volunteers In October 2024 And To Report Data In The First Half Of 2025
Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader